The Gaucher Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Gaucher Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gaucher Disease. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued products.

GlobalData tracks 46 drugs in development for Gaucher Disease by 38 companies/universities/institutes. The top development phase for Gaucher Disease is preclinical with 18 drugs in that stage. The Gaucher Disease pipeline has 41 drugs in development by companies and five by universities/ institutes. Some of the companies in the Gaucher Disease pipeline products market are: Yuhan, Sanofi and Kashiv BioSciences.

The key targets in the Gaucher Disease pipeline products market include Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45), Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80), and Acid Ceramidase (Acylsphingosine Deacylase or N Acylsphingosine Amidohydrolase or Acid Cdase or Putative 32 kDa Heart Protein or ASAH1 or EC 3.5.1.23).

The key mechanisms of action in the Gaucher Disease pipeline product include Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) Activator with 13 drugs in Phase II. The Gaucher Disease pipeline products include four routes of administration with the top ROA being Oral and nine key molecule types in the Gaucher Disease pipeline products market including Small Molecule, and Gene Therapy.

Gaucher Disease overview

Gaucher disease is a rare genetic disorder that occurs due to the lack of an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue, and seizures. Treatment includes enzyme replacement therapy.

For a complete picture of Gaucher Disease’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.